Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL)

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 3, 2007, Pages 469-477

  Eichhorst, Barbara ^a   Hallek, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

chronic lymphocytic leukemia; diagnosis; guidelines; minimal residual disease; prognosis; response criteria

Indexed keywords

CD38 ANTIGEN; NUCLEOSIDE ANALOG; PROTEIN KINASE ZAP 70; PURINE DERIVATIVE;

AUTOIMMUNE DISEASE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CRITERION VARIABLE; CYTOGENETICS; DISEASE ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LABORATORY TEST; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; PHENOTYPE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT INDICATION;

CLINICAL TRIALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASM, RESIDUAL; PRACTICE GUIDELINES; UNITED STATES;

EID: 34547880421     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.02.002     Document Type: Review

References (31)

1. Cheson B.D., Bennett J.M., Rai K.R., et al. Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL). Recommendations of the NCI-sponsored working group. American Journal of Hematology 29 (1988) 153-163
2. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
3. Müller-Hermelink H.K., Montserrat E., Catovsky D., et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Jaffe E.S., Harris N.L., Stein H., et al. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours (2001), IARCPress, Lyon 127-130
4. Catovsky D., Ralfkiaer E., and Müller-Hermelink H.K. T-cell prolymphocytic leukaemia. In: Jaffe E.S., Harris N.L., Stein H., et al. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours (2001), IARCPress, Lyon 195-196
5. Melo J.V., Catovsky D., and Galton D.A.G. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. British Journal of Haematology 63 (1986) 377-387
6. Marti G.E., Rawstron A.C., Ghia P., et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. British Journal of Haematology 130 (2005) 325-332
7. Moreau E.J., Matutes E., A'Hern R.P., et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). American Journal of Clinical Pathology 108 (1997) 378-382
8. Ibrahim S., Keating M., Do K.A., et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98 (2001) 181-186
9. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. The New England Journal of Medicine 348 (2003) 1764-1775
10. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine 351 (2004) 893-901
11. Orchard J.A., Ibbotson R.E., Davis Z., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363 (2004) 105-111
12. Lin K., Sherrington P.D., Dennis M., et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100 (2002) 1404-1409
13. Ghia P., Guida G., Stella S., et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101 (2003) 1262-1269
14. Binet J.L., Caligaris-Cappio F., Catovsky D., et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107 (2006) 859-861
15. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [see comments]. Blood 94 (1999) 1840-1847
16. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia [see comments]. Blood 94 (1999) 1848-1854
17. Hallek M., Langenmayer I., Nerl C., et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progression in early, non-smoldering chronic lymphocytic leukemia. Blood 93 (1999) 1732-1737
18. Keating M.J., Lerner S., Kantarjian H., et al. The serum ß2-microglobulin (ß2m) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 86 supplement I (1995) 606a
19. Reinisch W., Willheim M., Hilgarth M., et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. Journal of Clinical Oncology 12 (1994) 2146-2149
20. Sarfati M., Chevret S., Chastang C., et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 88 (1996) 4259-4264
21. Rai K.R., Sawitsky A., Cronkite E.P., et al. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219-234
22. Binet J.L., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1981) 198-204
23. Extermann M., Overcash J., Lyman G.H., et al. Comorbidity and functional status are independent in older patients. Journal of Clinical Oncology 16 (1998) 1582-1587
24. Dreger P., Brand R., Milligan D., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19 (2005) 1029-1033
25. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106 (2005) 4389-4396
26. Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Journal of Clinical Oncology 21 (2003) 2747-2753
27. Caballero D., Garcia-Marco J.A., Martino R., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clinical Cancer Research 11 (2005) 7757-7763
28. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 (2006) 885-891
29. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-Cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology 23 (2005) 2971-2979
30. Wendtner C.M., Ritgen M., Schweighofer C.D., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 (2004) 1093-1101
31. Bosch F., Ferrer A., Lopez-Guillermo A., et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British Journal of Haematology 119 (2002) 976-984